Publications

Cette section contient les publications du Groupe québécois de recherche en LMC-NMP

Publications du GQR LMC-NMP sur la LMC

Klil-Drori AJ, Azoulay L, Yin H, Gratton M-O, Harnois M, Chamakhi I, Delage R, Laneuville P, Mollica L, Olney HJ, Busque L, Assouline SE. Comparative effectiveness of generic Imatinib and brand-name Imatinib for the treatment of chronic myeloid leukemia https://ash.confex.com/ash/2015/webprogramscheduler/Paper80890.html

Busque L, Gratton M-O, Harnois M, Mollica L, Laneuville P, Olney HJ, Delage R, Assouline S. Real life analysis of CML management demonstrates that second-line therapy is frequently used but is prematurely discontinued for intolerance: report of the Groupe Quebecois de Recherche en LMC-NMP https://library.ehaweb.org/eha/2015

Klil-Drori AJ, Azoulay L, Yin H, Del Corpo A, Harnois M, Gratton M-O, Chamakhi I, Delage R, Mollica L, Laneuville P, Olney HJ, Busque L, Assouline SE. Timely Molecualre Monitoring and achievement of Major molecualre response in chronic Myeloid Leukemia. https://ashpublications.org/blood/article/128/22/3072/113741/Timely-Molecular-Monitoring-and-Achievement-of?searchresult=1

Adi J Klil-Drori, Hui Yin, Laurent Azoulay, Alexa Del Corpo, Michael Harnois, Michel-Olivier Gratton, Lambert Busque, Sarit Assouline. Persistence with generic imatinib for chronic myeloid leukemia: a matched cohort study. https://ashpublications.org/blood/article/130/Supplement%201/315/114398/Persistence-with-Generic-Imatinib-for-Chronic?searchresult=1

Klil-Drori AJ,Yin H, Azoulay L,Harnois M,Gratton MO, Del Corpo A, Mollica L, Busque L, Assouline SE for the GQR LMC-NMP. Early switch in tyrosine kinase inhibitor therapy and major molecular response in chronic myeloid leukemia: a prospective observational study using the Quebec CML registry. Am J Hematol. 2017 Oct;92(10):E602-E604. doi: 10.1002/ajh.24838. https://onlinelibrary.wiley.com/doi/10.1002/ajh.24838

Klil-Drori AJ, Yin H, Azoulay L, Del Corpo A, Harnois M, Gratton MO, Olney HJ, Delage R, Laneuville P, Mollica L, Busque L, Assouline SE; Groupe Québécois de Recherche en Leucémie Myéloïde Chronique et Néoplasies Myéloprolifératives (GQR LMC-NMP). Molecular monitoring of therapeutic milestones and clinical outcomes in patients with chronic myeloid leukemia Cancer. 2018 Nov 13. doi: 10.1002/cncr.31835.PMID:3042321. https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.31835

Klil-Drori AJ, Yin H, Azoulay L, Harnois M, Gratton MO, Busque L, Assouline SE. Persistence with generic imatinib for chronic myeloid leukemia: a matched cohort study. Haematologica. 2019 Jan 10. pii: haematol.2018.211235. doi: 10.3324/haematol.2018.211235. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6601075/

Del Corpo O, Harnois M, Busque L, Assouline S, Real-Life Use of Nilotinib for Chronic Phase CML Demonstrates Similar Efficacy and Rate of Cardiovascular Events As Enestnd. https://ashpublications.org/blood/article/138/Supplement%201/4602/481736/Real-Life-Use-of-Nilotinib-for-Chronic-Phase-CML?searchresult=1

Lambert Busque, Michael Harnois, Natasha Szuber, Robert Delage, Luigina Mollica, Harold Olney, Pierre Laneuville, Shireen Sirhan, Ghislain Cournoyer, Inès Chamakhi, Marc Lalancette, Danielle Talbot, Vincent Éthier, Pierre Desjardins, Sarit Assouline, QUÉBEC CML RESEARCH GROUP ANALYSIS OF TREATMENT PATTERNS IN CHRONIC MYELOGENOUS LEUKEMIA: SWITCHING IS DRIVEN BY INTOLERANCE AND SIMILAR ACROSS TYROSINE KINASE INHIBITORS AND LINES OF TREATMENT. https://library.ehaweb.org/eha/2022

Publications du GQR LMC-NMP sur les NMP

Eliane Nguyen, Michaël Harnois, Lambert Busque, Luigina Mollica, Sarit Assouline, Ines Chamaki, Harold Olney, Shireen Sirhan, Natasha Szuber, Secondary erythrocytosis is phenotypically distinct from polycythemia vera but associated with comparable rates of thrombosis at diagnosis. https://ashpublications.org/blood/article/136/Supplement%201/4/472722/Secondary-Erythrocytosis-Is-Phenotypically?searchresult=1

Simpson-Poirier K, Harnois M, Olney HJ, Sirhan S, Gratton MO, Assouline S, Laneuville P, Delage R, Mollica L, Busque L, Szuber N. Risk of infection in MPN patients in the era of Covid-19: A prospective multicenter study of 257 patients from the CML-MPN Quebec Research Group. Am J Hematol. 2021 Jun 1;96(6):E200-E203. doi: 10.1002/ajh.26159. Epub 2021 Mar 26. PMID: 33719144; PMCID: PMC8250202. https://onlinelibrary.wiley.com/doi/10.1002/ajh.26159

Nguyen E, Harnois M, Busque L, Sirhan S, Assouline S, Chamaki I, Olney H, Mollica L, Szuber N. Phenotypical differences and thrombosis rates in secondary erythrocytosis versus polycythemia vera. Blood Cancer J. 2021 Apr 15;11(4):75. doi: 10.1038/s41408-021-00463-x. PMID: 33859172; PMCID: PMC8050282. https://www.nature.com/articles/s41408-021-00463-x

Natasha Szuber, Judith Jolin, Michael Harnois, Patterns of Care and Outcomes in Adolescents and Young Adults with Myeloproliferative Neoplasms: A Multicenter Population-Based Study. https://ashpublications.org/blood/article/138/Supplement%201/3650/479792/Patterns-of-Care-and-Outcomes-in-Adolescents-and?searchresult=1

Judith Jolin, Michael Harnois, Luigina Mollica, Pierre Laneuville, Robert Delage, Harold J. Olney, Shireen Sirhan, Lambert Busque, Natasha Szuber, Very Elderly Patients with Myeloproliferative Neoplasms: Phenotypic Distinctions and Prognostic Determinants of Complications and Mortality. https://ashpublications.org/blood/article/138/Supplement%201/2572/478642/Very-Elderly-Patients-with-Myeloproliferative?searchresult=1

Natasha Szuber, Michael Harnois, Robert Delage, Shireen Sirhan and Lambert Busque, Higher Rates of Perioperative Thrombosis and Distinct Management Practices in Secondary Erythrocytosis Versus Polycythemia Vera. https://ashpublications.org/blood/article/140/Supplement%201/5661/489771/Higher-Rates-of-Perioperative-Thrombosis-and?searchresult=1

Audrey Desilets, Michael Harnois, Lambert Busque and Natasha Szuber, Prognostic Impact of High Calreticulin Variant Allele Frequency in Patients with Myeloproliferative Neoplasms. https://ashpublications.org/blood/article/140/Supplement%201/9700/487158/Prognostic-Impact-of-High-Calreticulin-Variant?searchresult=1

Alisa Poullet, Lambert Busque, Shireen Sirhan, Robert Delage, Ghislain Cournoyer, Ines Chamakhi, Danielle Talbot, Luigina Mollica, Daniele Marceau, Vincent Ethier, Pierre Desjardins, Harold J. Olney, Michaël Harnois, Natasha Szuber. Prospective Symptom Burden Analysis in 784 Patients with Myeloproliferative Neoplasms: High Burden Correlates with Inflammatory/Genetic Biomarkers and Reduced Survival. https://ashpublications.org/blood/article/142/Supplement%201/917/499416/Prospective-Symptom-Burden-Analysis-in-784?searchresult=1

Natasha Szuber, Steve Dagenais-Bellefeuille, Mégane Tanguay, Awatef Shehabeldeen, Saima Ahmed, Michaël Harnois, Jaroslav F. Prchal, Harold J. Olney, Lambert Busque, Shireen Sirhan. Perioperative Outcomes and Management in Patients with Myeloproliferative Neoplasms: A Multicentric Retrospective Analysis of 354 Surgical Interventions. https://ashpublications.org/blood/article/142/Supplement%201/3183/503922/Perioperative-Outcomes-and-Management-in-Patients?searchresult=1

Publications en collaboration avec d’autres groupes

Christopher M Hillis, MD FRCPC, Lambert Busque, MD PhD FRCPC, Julie Stakiw, MD, Donna L. Forrest, MD FRCPC. Adherence to Chronic Myeloid Leukemia Monitoring and Treatment Guidelines in Canadian Registries. https://ashpublications.org/blood/article/128/22/3079/113911/Adherence-to-Chronic-Myeloid-Leukemia-Monitoring

Sarit Assouline, Maria Cristina Miggiano, Elisabetta Abruzzese, Chiara Elena, Giovanni Caocci, Susanne Saussele, Francesca Lunghi, Alberto Alvarez-Larran, Barbara Mora, Sigi Petrela, Laura Antolini, Carlo Gambacorti-Passerini, Alessandra Iurlo Risk of Progression in Chronic Phase – Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation (TFR-PRO study): Preliminary Results. https://ashpublications.org/blood/article/138/Supplement%201/1476/480626/Risk-of-Progression-in-Chronic-Phase-Chronic

Steffen Koschmieder, Clemens Schulte, Eyck von der Heyde, Lambert Busque, Françoise Boyer-Perrard, Timothy Devos, Francesco Passamonti, Mike W. Zuurman, Carole Paley, Geralyn Gilotti, Wendy Y. Cheng, Chi Gao, Mu Cheng, Melody Wu, Mei Sheng Duh, Claire N. Harrison, Characteristics of High-Risk Polycythemia Vera Patients with Suboptimal Response to First-Line Therapy Who Switched to Ruxolitinib Vs Those Who Did Not Switch: Findings from PV-Switch, a Multinational, Retrospective Chart Review Study. https://ashpublications.org/blood/article/138/Supplement%201/3646/479787/Characteristics-of-High-Risk-Polycythemia-Vera

Szuber N, Toliopoulos P, Busque L, Cerquozzi S, Foltz L, Gupta V, Tefferi A, Vannucchi AM, Hillis C, Leber B, Maze D, Prchal J, Olney HJ, Sirhan S, Perioperative management of myeloproliferative neoplasms: A pan-Canadian physician survey and international expert opinion, Am J Hematol. 2022 Sep 23. doi: 10.1002/ajh.26739. https://onlinelibrary.wiley.com/doi/10.1002/ajh.26739

Khadadah FM, Cerquozzi S, Olney HJ, Fraga C, Dudebout J, Xenocostas A, Finn N, Ethier V, Savoie ML, Busque L, Jamani K, Kuruvilla P, Faught C, Leber B, Kaedbey R, Assouline SE, Kim D. Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy, Leuk Res 2023 Oct. doi: 10.1016/j.leukres.2023.107374. https://www.sciencedirect.com/science/article/abs/pii/S0145212623006392?via%3Dihub

Zambrotta GPM, Nicolini FE, Assouline S, Busque L, Pungolino E, Abruzzese E, Miggiano MC, Elena C, Alvarez-Larran A, Triguero A, Iurlo A, Bucelli C, Cerrano M, Capodanno I, Lunghi F, le Coutre P, Galimberti S, Caocci G, Maffioli M, Stagno F, Saussele S, Piazza R, Druker BJ, Fava C, Guglielmana V, Colombo F, Antolini L, Gambacorti-Passerini C. Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR-PRO study. Am J Hematol 2023 Aug 30. doi: 10.1002/ajh.27073. https://onlinelibrary.wiley.com/doi/full/10.1002/ajh.27073

Paola Guglielmelli, Natasha Szuber, Naseema Gangat, Giulio Capecchi, Chiara Maccari, Lambert Busque, Omer Karrar, Maymona Abdelmagid, Manjola Balliu, Alessandro Atanasio, Ilaria Sestini, Audrey Desilets, Giuseppe Gaetano Loscocco, Giada Rotunno, Marie-Christine Meunier, Michael Harnois, Ayalew Tefferi, Alessandro Maria Vannucchi. Calr Variant Allele Frequency in Essential Thrombocythemia: Molecular Associations and Impact on Disease Phenotype and Outcome. https://ashpublications.org/blood/article/142/Supplement%201/6328/504791/Calr-Variant-Allele-Frequency-in-Essential?searchresult=1

England JT, Szuber N, Sirhan S, Dunne T, Cerquozzi S, Hill M, Villeneuve PJA, Ho JM, Sadikovic B, Bhai P, Krishnan N, Dowhanik S, Hillis C, Capo-Chichi JM, Tsui H, Cheung V, Gauthier K, Sibai H, Davidson MB, Bankar A, Kotchetkov R, Gupta V, Maze D. Clinical Features and Long-Term Outcomes of a Pan-Canadian Cohort of Adolescents and Young Adults with Myeloproliferative Neoplasms: A Canadian MPN Group Study. Leukemia. 2024 Feb 6. doi: 10.1038/s41375-024-02155-4. Online ahead of print. PMID: 38321107. https://www.nature.com/articles/s41375-024-02155-4

Guglielmelli P, Szuber N, Gangat N, Capecchi G, Maccari C, Harnois M, Karrar O, Abdelmagid M, Balliu M, Nacca E, Atanasio A, Sestini I, Desilets A, Loscocco GG, Rotunno G, Busque L, Tefferi A, Vannucchi AM. CALR mutation burden in essential thrombocythemia and disease outcome. Blood. 2024 Jan 22:blood.2023023428. doi: 10.1182/blood.2023023428. Online ahead of print. PMID: 38252902. https://ashpublications.org/blood/article/doi/10.1182/blood.2023023428/514710/CALR-mutation-burden-in-essential-thrombocythemia?searchresult=1